Virtual Library

Start Your Search

S. Kim



Author of

  • +

    Best abstracts selected from submissions 6 (ID 7)

    • Event: ACLC 2018
    • Type: Oral Session
    • Track:
    • Presentations: 1
    • +

      OA11 - First-Line Nivolumab + Ipilimumab in Asian Patients With Advanced NSCLC and High TMB (?10 mut/Mb): Results From CheckMate 227 (ID 166)

      16:20 - 17:00  |  Author(s): S. Kim

      • Abstract
      • Slides

      Background:
      CheckMate 227 (NCT02477826), a randomized, open-label, multipart, phase 3 study, demonstrated significant progression-free survival (PFS) benefit with first-line nivolumab + ipilimumab versus histology-based, platinum-doublet chemotherapy (PT-DC) in patients with advanced non-small cell lung cancer (NSCLC) and high tumor mutational burden (TMB; ?10 mutations/megabase [mut/Mb]). Safety was manageable and consistent with prior reports for nivolumab + low-dose ipilimumab. Here we report efficacy and safety of nivolumab + ipilimumab versus PT-DC in the Asian subpopulation from CheckMate 227.


      Method:
      Patients with chemotherapy-na

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    Poster Session (ID 8)

    • Event: ACLC 2018
    • Type: Poster Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
    • +

      P018 - Afatinib Named Patient Use Program in Advanced NSCLC with Progression on Prior Therapy: Experience from Asian Centers (ID 93)

      00:00 - 00:00  |  Author(s): S. Kim

      • Abstract

      Background:
      A global named patient use (NPU) program for afatinib in patients with advanced/metastatic NSCLC who had progressed during prior therapy was conducted between May 2010 and January 2016 (Cappuzzo et al (2018). Here we describe outcomes for patients at Asian centers, including 840 patients treated at centers in Taiwan.


      Method:
      Eligible patients had progressed after clinical benefit on prior erlotinib/gefitinib and/or had an activating EGFR/HER2 mutation, had exhausted all other treatments, and were ineligible for afatinib trials. Patients received afatinib (starting dose: 30